Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$2.66 USD

2.66
2,503,145

-0.11 (-3.97%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $2.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

by Zacks Equity Research

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.

Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down

by Zacks Equity Research

Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.

Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.

BioNTech (BNTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On BioNTech's (BNTX) third-quarter earnings call, investors will likely focus on the sales performance of its COVID-19 vaccine Comirnaty, developed in partnership with Pfizer.

Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.

Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 138.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on sales numbers of Pfizer's (PFE) COVID-19 vaccine and COVID pill, Paxlovid.

Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.

What's in Store for Gilead (GILD) This Earnings Season?

by Zacks Equity Research

Investors focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports third-quarter 2022 results.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?

by Zacks Equity Research

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have jumped.

The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

by Zacks Equity Research

CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.